NIRCO med‎ > ‎drugs‎ > ‎Antithrombotika‎ > ‎Faktor IIa-Inhibitoren‎ > ‎

Bivalirudin

Indikationen/Anwendungsmöglichkeiten: is approved for use in patients with (1):
  • unstable angina who are undergoing percutaneous transluminal coronary angioplasty,
  • for the treatment of patients with, or at risk for, HIT,
  • HIT and thrombosis syndrome undergoing PCI,
  • PCI with provisional use of glycoprotein IIb/IIIa antagonist therapy.
  • In these indications, bivalirudin is intended for concomitant use with acetylsalicylic acid.
Warnhinweise und Vorsichtsmassnahmen: is partially (approximately 20%) renally eliminated, its use may require dose adjustment in renally impaired patients to avoid accumulation (1).

Eigenschaften/Wirkungen: is a parenteral, bivalent direct thrombin inhibitor that, unlike heparin, inhibits both free and fibrin-bound thrombin and has low immunogenic potential (1).

Pharmakokinetik: it has a rapid onset of action and is predominantly metabolized via proteolysis with subsequent renal excretion (1).

Referenzen:
  1. Bivalirudin. Thromb Haemost. 2008;99:830-9: pdf.